Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder

JAMA Intern Med. 2023 Sep 1;183(9):1023-1026. doi: 10.1001/jamainternmed.2023.2826.
No abstract available

Plain language summary

This cohort study examined the association between out-of-pocket costs for an initial buprenorphine prescription and its discontinuation among commercially insured US adults with opioid use disorder.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Analgesics, Opioid / therapeutic use
  • Buprenorphine* / therapeutic use
  • Health Expenditures
  • Humans
  • Insurance, Health
  • Narcotic Antagonists / therapeutic use
  • Opiate Substitution Treatment
  • Opioid-Related Disorders* / drug therapy
  • United States

Substances

  • Buprenorphine
  • Narcotic Antagonists
  • Analgesics, Opioid